Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576543 | 0.87 | SLC6A3 (0.46) | MEN1KMT2ASLC6A3LMNASMN1; SMN2 | |
| SCHEMBL1788615 | 0.83 | CYP4F2 (0.57) | MEN1KMT2ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL17067761 | 0.82 | SLC6A3 (0.45) | SLC6A3LMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL27881584 | 0.82 | CA12 (0.59) | MEN1KMT2ALMNATSHRGAA | |
| SCHEMBL8336888 | 0.81 | ACMSD (0.45) | SLC6A3LMNAALDH1A1NPSR1SLC6A4 | |
| SCHEMBL23635957 | 0.81 | PDE4B (0.49) | KMT2ALMNAHPGDKDM4EGAA | |
| SCHEMBL3828063 | 0.81 | ACMSD (0.41) | KMT2ASLC6A3LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2403289 | 0.81 | KDM4E (0.55) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL18640659 | 0.81 | TSHR (0.50) | SLC6A3LMNAALDH1A1NPSR1TSHR | |
| SCHEMBL30842192 | 0.81 | PDE4B (0.49) | KMT2ALMNAHPGDKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851072-B2 | Inhibitors of Rho/MRTF/SRF-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851072-B2 | Inhibitors of Rho/MRTF/SRF-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2019195641-A2 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195641-A2 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190308947-A1 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-10 | — | — | US | disclosed |
| US-20190308947-A1 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-10 | — | — | US | disclosed |
| WO-2017051319-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308947-A1 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | RHOXF2, BPTF, SREBF1 | MEN1 2730/4885KMT2A 1167/4885SLC6A3 1761/4885 |
| US-10851072-B2 | Inhibitors of Rho/MRTF/SRF-mediated gene transcription and methods for use of the same | RHOXF2, BPTF, SREBF1 | MEN1 2730/4885KMT2A 1167/4885SLC6A3 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.